Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Heart & blood · 2024

Rapiblyk (landiolol)

The FDA approved Rapiblyk (landiolol) on November 22, 2024 to treat supraventricular tachycardia.
Brand name
Rapiblyk
Generic name
landiolol
FDA approval date
November 22, 2024
Approved use (FDA wording)
To treat supraventricular tachycardia
Company
Aop Hlth Us
Application
NDA217202
Dosage form / route
POWDER · INTRAVENOUS
Boxed warning on label
Not listed
Category on this site
Heart & blood

Indications and usage, from the FDA label

RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia. RAPIBLYK is a beta adrenergic blocker indicated for the short-term reduction of ventricular rate in: adults with supraventricular tachycardia including atrial fibrillation and atrial flutter ( 1 ), and pediatric patients with supraventricular tachycardia.( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.